Literature DB >> 2040383

Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons.

D K McCulloch1, D J Koerker, S E Kahn, S Bonner-Weir, J P Palmer.   

Abstract

In vivo beta-cell function tests are used increasingly in humans during the preclinical phase of insulin-dependent diabetes mellitus (IDDM), but the severity of the beta-cell loss responsible for the abnormalities seen in these tests is unknown. We have measured several physiological beta-cell function tests--fasting plasma glucose, glucose disappearance constant, fasting insulin, acute insulin responses to arginine (AIRarginine) and glucose (AIRglucose), and glucose potentiation of AIRarginine (delta AIRarginine/delta G) and two direct objective measurements (pancreatic insulin content [PIC] and quantitative beta-cell mass)--in adolescent male baboons (Papio anubis/cyanocephalus). We have correlated in vivo measurements obtained within 3 days after the animals were killed with in vitro estimates of PIC and beta-cell mass in 15 animals, (2 nondiabetic requiring insulin treatment and 13 after varying doses of streptozocin to induce degrees of beta-cell damage ranging from normoglycemia to severe hyperglycemia). There was a strong linear correlation between beta-cell mass and PIC (r = 0.79, P less than 0.001). Physiological measures of beta-cell function were significantly correlated with both PIC and beta-cell mass. The correlations between physiological measures and beta-cell mass were linear and intercepted the beta-cell mass axis at 0.15-0.2 g, suggesting that in vivo measures of beta-cell function approach 0 when there is still approximately 40-50% of the beta-cell mass detectable histologically. With PIC, the linear correlations intercepted the axes close to 0. These findings provide considerable validity to the measurements of beta-cell function used in preclinical IDDM in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040383     DOI: 10.2337/diab.40.6.673

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  38 in total

1.  Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.

Authors:  J P Palmer
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model.

Authors:  Taeko Uonaga; Kentaro Toyoda; Teru Okitsu; Xiaotong Zhuang; Shunsuke Yamane; Shinji Uemoto; Nobuya Inagaki
Journal:  Islets       Date:  2010 Jul-Aug       Impact factor: 2.694

3.  Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands.

Authors:  John Virostko; Joseph Henske; Laurent Vinet; Smaragda Lamprianou; Chunhua Dai; Aramandla Radhika; Ronald M Baldwin; Mohammad S Ansari; Franz Hefti; Daniel Skovronsky; Hank F Kung; Pedro L Herrera; Todd E Peterson; Paolo Meda; Alvin C Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

4.  Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients.

Authors:  D Hirsch; J Odorico; J S Danobeitia; R Alejandro; M R Rickels; M Hanson; N Radke; D Baidal; D Hullett; A Naji; C Ricordi; D Kaufman; L Fernandez
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

5.  Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model.

Authors:  Chengyang Liu; Brigitte Koeberlein; Michael D Feldman; Rebecca Mueller; Zhonglin Wang; Yanjing Li; Kristin Lane; Clifford C Hoyt; John E Tomaszewski; Ali Naji; Michael R Rickels
Journal:  Endocrinology       Date:  2012-02-21       Impact factor: 4.736

6.  Arginine is preferred to glucagon for stimulation testing of β-cell function.

Authors:  R Paul Robertson; Ralph H Raymond; Douglas S Lee; Roberto A Calle; Atalanta Ghosh; Peter J Savage; Sudha S Shankar; Maria T Vassileva; Gordon C Weir; David A Fryburg
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

7.  Automated quantification of pancreatic β-cell mass.

Authors:  Maria L Golson; William S Bush; Marcela Brissova
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-04-22       Impact factor: 4.310

8.  Different effects of glucose and glyburide on insulin secretion in rat pancreatic islets pre-exposed to interleukin-1 beta. Possible involvement of K+ and Ca2+ channels.

Authors:  M Buscema; A M Rabuazzo; C Vinci; V Caltabiano; R Vigneri; F Purrello
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

9.  Human islet purification: a prospective comparison of Euro-Ficoll and bovine serum albumin density gradients.

Authors:  D R Chadwick; G S Robertson; H Contractor; S Swift; S Rose; S T Thirdborough; R Chamberlain; R F James; P R Bell; N J London
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

10.  Ongoing beta-cell turnover in adult nonhuman primates is not adaptively increased in streptozotocin-induced diabetes.

Authors:  Yoshifumi Saisho; Erica Manesso; Alexandra E Butler; Ryan Galasso; Kylie Kavanagh; Mickey Flynn; Li Zhang; Paige Clark; Tatyana Gurlo; Gianna M Toffolo; Claudio Cobelli; Janice D Wagner; Peter C Butler
Journal:  Diabetes       Date:  2011-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.